Ignite Creation Date:
2024-05-06 @ 7:25 PM
Last Modification Date:
2024-10-26 @ 3:06 PM
Study NCT ID:
NCT06009835
Status:
RECRUITING
Last Update Posted:
2023-08-24
First Post:
2023-08-19
Brief Title:
DOTrDOTa Algorithm Guidance for Refractory Solid Tumors
Sponsor:
Tianjin Medical University Second Hospital
Organization:
Tianjin Medical University Second Hospital
Study Overview
Official Title:
An Open Single Center Clinical Study Based on DarwinOncoTreatTM DOTr and DarwinOncoTargetTM DOTa Algorithm Guidance for Treating Solid Tumor Patients Who Are Exhausted or Unable to Tolerate Standard Treatment Regimens
Status:
RECRUITING
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is an open single center clinical study targeting solid tumor patients who have exhausted or cannot tolerate standard treatment regimens The main purpose of this study is to investigate the feasibility efficacy and safety of selecting treatment regimens based on DOTrDOTa results for solid tumor patients who have exhausted or cannot tolerate standard treatment regimens
Detailed Description:
Both OncoTargetDarwinOncoTargetTM DOTa which identifies high-affinity inhibitors of individual master regulator MR proteins and OncoTreatDarwinOncoTreatTM DOTr which identifies drugs that invert the transcriptional activity of hyperconnected MR modules produced highly significant 30-day disease control rates 68 and 91 respectively
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None